Drugs / RotaTeq(R)
RotaTeq(R)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00767364 | Jul 2009 → Oct 2012 | short bowel syndrome | Children's Hospital of Michigan | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-05-25 | Merck Sharp & Dohme LLC | Government of Rwanda Introduces Merck’s ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus merck.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RotaTeq(R) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00767364 ↗ |
| Known as | RotaTeq | “The objective of the study is the assessment of safety and tolerability of the oral RotaTeq® vaccine for all infants participating in the study.” NCT00767364 ↗ |
| Known as | RotaTeq vaccine (Merck and Co.) | “RotaTeq vaccine (Merck and Co.)” NCT00767364 ↗ |
| Modality | Vaccine | “Oral vaccine for prevention of rotavirus infection, 3 dose series” NCT00767364 ↗ |
| Route | Oral | “oral rotavirus vaccine” NCT00767364 ↗ |